

Docket No. 263361US0PCT

10/516945
DT05 Rec'd PCT/PTO 16 DEC 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Andrea CAPOCCHI

SERIAL NO: New U.S. PCT Application Based on PCT/EP03/06142

GAU:

FILED: Herewith

EXAMINER:

FOR: A PROCESS FOR THE PREPARATION OF PIROXICAM: B-CYCLODEXTRIN INCLUSION COMPOUNDS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references cited in the International Search Report and listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon

Registration No. 24,618

Corwin P. Umbach, Ph.D.
Registration No. 40,211

Surinder Sachar

Registration No. 34,423

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 263361US0PCT		SERIAL NO. New U.S. PCT Application Based on PCT/EP03/06142	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Andrea CAPOCCHI			
				FILING DATE Herewith		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	5,164,379	11/17/92	KOSLO, Randy J. et al			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO	0 153 998	09/11/85	EP		NO	
	AP	95/28965	11/02/95	WO		NO	
	AQ	91/13100	09/05/91	WO		NO	
	AR	0 295 476	12/21/88	EP		NO	
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AW	ACERBI, D. et al: "Biopharmaceutical optimisation of. beta.- cyclodextrin inclusion compounds." DRUG INVESTIGATION, 2(Suppl. 4) pages 29-36, 1990.					
	AX	NAGARSENKER, Mangal S. et al: "Influence of hydroxypropyl. beta.- cyclodextrin on dissolution of piroxicam and on irritation to stomach of rats upon oral administration" INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 59, no. 4, pages 174-180, 1997.					
	AY						
	AZ					<input type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							